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sequentiallyin DAP & CSOSpacing alone for 3-mo periods. Arrhythmia-free
intervals were evaluated in the 3 mos prior to device implant (control), during
RA pacing (DAP &/or CSoa) at last follow-up (mean duration 9 + 3 mos) &
in the first 3-mo CSOSpacing segment alone. Results: The pacing threshold
at the CSOSat implant was 1.2 + 0.4 vs 1.1 + 0.3 V at the high RA (p >
0.2). There was no significant threshold change at the CSOSduring follow-
UP.There was 1 CS lead dislodgement intraoperatively requiring immediata
repositioning. 3 pts experienced AF recurrences in the CSOSpacing mode.
Control & CSOSpacing arrhythmia-free intervals are shown in the figure. The
total arrhythmia-free interval during RA pacing was 179+ 117days.
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Conclusion: In pte with refractow AF & frequent recurrences, long-term
atrial pacing can be safely performed at the CSOS.This new pacing mode
also increases arrhythmia-free intervals in AF pts.
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1717-61 CornPa~ativaEvaluation~fAut~mati~Mode
SwltchmgAlgorithmsin RateControlDuringAF
s.-K.Leung 1, C.-P. Leu, C. Lam 1, H.-F.Tse, F.Chung, M.-O. Tang,
G. Ayres. Kwong Wah Hospital, Hong Kong, Queen Mary Hospital, Hong
Kong
Background: An optimal automatic mode switch (AMS) algorithm should
correctly detect atrial fibrillation (AF), avoid an inappropriate increase in
ventricular rate to onset of AF, maintain a stable ventricular rate during AF
and facilitate rapid AV re-synchronization when AF terminated. However,the
relative efficacy of current AMS during AF have not been directly compared.
We recorded unfiltered bipolar right atrial electrogram of sinus rhythm and
AF during elelctrophysiological study in 15 patients with paroxysmal AF and
chronic AF after transvenous defibrillation onto high fidelity tapes by analog
tape recorder. A total of 135 rhythms were replayed onto 3 dual chamber
pacemakers (PM) with 3different AMSalgorithme: TheraDR 7940, Medtronic
Inc.: uses running average of atrial rate (mean atrial rate); Marathon 294-
09, Intermedics Inc.: monitom the consecutive atrial rate (rate and runs)
and MetaDDDR 1254 Teletronic inc.: monitors the sensed atrial rate in the
PVARP (atrial rate monitor). The PM were programmed to a lower rate of 50
and upper rate of 150, TARP at 410 ms, AMS rate at 175 bpm, AMS counts
to5 and the atrial sensitivity at half of the measured atrial P wave amplitude.
The response of the PM during, at the onset and termination of the AF were
recorded by an electrocardiographic signal recorder (Mingograph, Siemens).
Results: (table) The mean programmed atrial sensitivity was 2.1 mV.
AF onset DuringAF withAMS AF ceases
latency No. of Shortest Mean Maximum No. of Latencyfor
for AMS beats RR RR chenge beats AV reeyn-
(s) tracked at (ins) (ins) in RR (ins) tracked at chroni-
.,
>100 bpm >100 bpm zation(s)
TheraDR 13 19.1 577 928 44 1.6 143 l22
i ub & i?b + 22C &29 * 2C * 0,4
Marsthon 4 7.3 538 1006 672 17 3.4 Lto.7a
* 1.4 l3.7 l76C +49 * 84C l68a
MetaDDDR 14 17.7 034 951 346 14 5.9 l 1.1s
+S,tb+@ * 114C +50 * 109C * 5.sa
a P <0.05 comparedto Thera, b P <0.05 compsredto Marathon,c P <0.05 byANOVA.
Conclusion: The AMS algorithm monitoring the mean atrial rate gave a
stable and smooth decrease in pacing rate during AMS but resulted in a
faster pacing rate at the onset of AF, delay AMS response and prolonged
the resumption of AV synchrony when AF terminated. AMS algorithm which
used the rate and runs criteria gave a fast onset and recove~ from ~heAMS
response but reeulted in a fluctuating ventricular respanse during the AF.
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SymptomsintheScandinavianSimvastatinSurvival
Study(4S)
J. Kjekahus1,T.R. Padersen2, K. Pyorala3, A.G. Olsson4 for the
Scandinavian Simvastatin Study Group. ‘ Nationa/Hospita/, Os/o, Norway
2Aker Hoapita/, Oslo, NorwaH 3Kuopio University Hospital, Kuopio,
Finland, 4 FaculfyofHeafth Sciences, Linkdping, Sweden
The Scandinavian Simvastatin Survival Study (4S) showad that simvastatin
20-40 mg daily reduced the risk of death by 30% (p = 0.0003) over 5.4 yeare
in patients with CHD, due to a 42% reduction in CHD death. The risk of
hospital-verlfiad nonfatal myocardial infarction and that of revascularization
procedures both fell by 37%. Patiente were askad at each visit abut new
or worsening symptoms of any kind, and also underwent an annual phyaical
examination. We now report the effect of simvastatin on ischemic symptome
and eigns:
Patisntswithnew Plscsbo Simvastatin Relative tisk P
or worsening n. 2223 n = 2221 (95”/4cl)
Totel(o/o) Total (OA)
Anginapectoris 725 (33) 56S (26) 0,74 (0,67-0.S3) <0.0001
Intermittentclaudication S1 (3.6) 52 (2,3) 0.62 (0.44-0.SS) 0,008
One or more bruit 92 (4.1) 66 (3,0) 0.69 (0.50-0.95) 0,026
Carotidbruit 45 (2.0) 24 (1.1) 0.52 (0.32-0.S5) 0.009
Femoral bruit 43 (1.9) 39 (1.6) 0.s9 (0.5s-1 ,37) 0.594
In addition to a clear effect on angina pactoris, cholesterol-lowering with
simvastatin appears to exerl a general anti-atherosclerotic effect that is not
limited to the coronary bed. This is consistent with the previously reportad
30% reduction in cerebrovascular events, with 98 patients with such evente
in the placebo group and 70 in the simvastatin group (p = 0.024).
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[716-21 Benefitof CholesmrolRedutiionwithPrarastsitin,n
Post-MlPatientsIrrespectiveof FastingGlucose
Levels
R. Goldberg, L. Moye, B. Howard, W.J. Howard, M. Mellies, F. Sacks,
E. Braunwald. University of Miami, Miami FL, USA, Brigham and Women’s
Hospital, Boston, MA, USA
Cholesterol and Recurrent Events (CARE) was a secondary prevention trial
evaluating the benefit Ofpravastatin in post Ml patients with average choles-
terol levels (<240 mgfdl). The study population included 714 (i7.2~o) of
patients with diabetes by history or newly diagnosed, and 127 (3.1%) of
patients who demonstrated glucose intolerance. A prospectively planned
objective of the CARE diabetic substudy was the evaluation of a threshold
level for increased risk of clinical endpoints relative to levels of fasting glu-
cose (FBS). For this analysis, combined evente of fatal CHD, non-fatal Ml,
PTCA or CABG were used. A second objective was to assess the impact
of cholesterol reduction with pravastatin intervention in patients above and
below the threshold value. The incidence rate of events (and relative riak)
was found to increase with increasing FBS in both placebo and pravastatin
groups. At FBS >120 m~dl the relative risk was double that of FBS s 120
mg/dl. A significant (p c 0.001, Cl 0.67, 0.89) 23% decrease in risk was seen
with pravastatin treatment in patients with FBS s 120 mg/dl. A similar 28%
decrease in relative risk was seen with FBS z 120 (p = 0.04, Cl 0.55, 0.99).
An evaluation of attributable risk for patienta with FBSs 120 mg/dl revealed
that prevastatin therapy preventad at least one event in 52 patienta/10CSI
treated; treatment of patients with FBS >120 mg/dl preventad events in 89
patienta/1000 treated.
This study demonstrates that risk increases with increasing FBSlevel, and
that a “threshold” FBS of z 120 mgldl is associated with double the risk for
recurrent cardiovascular events. Pravastatin therapy resulted in a significant
23-26% reduction in combined clinical events irrespective of fasting glucose
levels in post-Ml patients with normal cholesterol levels.
